Skip to content

Microvascular function and psychological factors in heart failure patients treated with cardiac resynchronisation therapy (CRT)

Microvascular function and psychological factors in heart failure patients treated with cardiac resynchronisation therapy (CRT) - Microvascular function, psychological factors and CRT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31791
Enrollment
55
Registered
2008-05-20
Start date
2008-02-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac failure congestive heart failure

Interventions

None listed

Sponsors

TweeSteden ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: diagnosis ofchronic heart failure with a left ventricular ejection fraction of 40% or less being on optimal medical therapy NYHA functional class III/IV QRS duration of >=120msec In addition, at least one of the following echocardiographic criteria has to be fulfilled: an aortic pre-ejection delay>140msec, an interventricular mechanical delay>40 msec, or delayed activation of the posterolateral left ventricular wall

Exclusion criteria

Exclusion criteria: Inability to read, write or understand Dutch, a history of psychiatric illness other than mood disorders (depression/anxiety), significant cognitive impairments (e.g. dementia) or life-treating co morbidities (e.g. cancer).

Design outcomes

Primary

MeasureTime frame
Primary: Microvascular function as measured by blood flow response to endothelium-dependent and endothelium-independent vasoactieve stimuli (acetylcholine, nitroprusside, local heating); health status; cardiac symptoms; health care consumption.

Secondary

MeasureTime frame
Secondary: Mortality; morbidity (defined as hospitalisation for cardiac reasons). The primary endpoint, health care consumption, and the secondary endpoints, mortality and morbidity, will be assessed at T4 (i.e. 14 months post-CRT), with the information being obtained through the patients* medical records.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)